腹主动脉瘤腔内修复术中预防性肠系膜下动脉栓塞随机临床试验的五年随访
单中心平行组非盲随机临床试验纳入T2EL高危患者(通畅的肠系膜下动脉≥3 mm、腰椎动脉≥2 mm或主髂动脉型动脉瘤),按1:1随机分为EVAR联合IMA栓塞组与单纯EVAR组各53例。5年随访显示IMA栓塞组T2EL发生率28.3% vs 非栓塞组54.7%(P = .006),T2EL相关瘤囊增大≥5 mm豁免率及瘤囊缩小≥5 mm累积发生率均显著更高。
要点
- IMA栓塞组5年T2EL发生率28.3%,非栓塞组54.7%(P = .006)
- 5年T2EL相关瘤囊增大≥5 mm豁免率95.5% vs 73.6%(P = .021)
- 5年瘤囊缩小≥5 mm累积发生率54.2% vs 33.6%(P = .039)
核心结论
- 在高危T2EL患者中,EVAR术中预防性IMA栓塞可降低T2EL发生率并改善瘤囊相关结局。
- 如将预防性IMA栓塞限于T2EL高危患者,采用较低的门槛可能更为合适。
研究设计与样本
- 单中心、平行组、非盲随机临床试验,纳入T2EL高危患者(通畅IMA合并IMA直径≥3 mm、腰椎动脉直径≥2 mm或主髂动脉型动脉瘤之一)。
- 参与者按1:1随机分为EVAR联合IMA栓塞组与不栓塞组,每组各53例;另分析T2EL低风险患者结局。
- 主要终点为T2EL发生,次要终点包括瘤囊变化与再干预。
主要发现
- T2EL发生于IMA栓塞组28.3% vs 非栓塞组54.7%(P = .006)。
- 5年T2EL相关瘤囊增大≥5 mm豁免率IMA栓塞组95.5% vs 非栓塞组73.6%(P = .021)。
- 5年瘤囊缩小≥5 mm累积发生率IMA栓塞组54.2% vs 非栓塞组33.6%(P = .039)。
- 5年T2EL相关瘤囊增大≥10 mm豁免率IMA栓塞组100% vs 非栓塞组90.4%(P = .019)。
- 低风险组结局优于非栓塞组,与IMA栓塞组相当。
临床怎么用
- 作者认为,如将预防性IMA栓塞限于T2EL高危患者,采用较低的门槛可能更为合适。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Type II endoleak (T2EL) is the most common type of endoleak after endovascular aneurysm repair (EVAR) and a common indication for reintervention due to late sac enlargement. Although pre-emptive embolization of the inferior mesenteric artery (IMA) has been proposed to prevent this, no studies have prospectively demonstrated its efficacy. This study aimed to prove the validity of IMA embolization during EVAR in selective cases by analyzing the mid-term outcomes of a randomized clinical trial (RCT). METHODS: This single-center, parallel-group, non-blinded RCT included participants at high risk of T2EL, characterized by a patent IMA in conjunction with one or more following risk factors: a patent IMA ≥3 mm in diameter, lumbar arteries ≥2 mm in diameter, or an aortoiliac-type aneurysm. The participants were randomly assigned to two groups in a 1:1 ratio: one undergoing EVAR with IMA embolization and the other without. The primary endpoint was T2EL occurrence. The secondary endpoints included aneurysm sac changes and reintervention. In addition to RCT participants, outcomes of patients with low risk of T2EL were also analyzed. RESULTS: The embolization and non-embolization groups each contained 53 patients. Five-year follow-up after the last patient enrollment revealed that T2ELs occurred in 28.3% and 54.7% of patients in the IMA embolization and non-embolization groups, respectively (P = .006). Both freedom from T2EL-related sac enlargement ≥5 mm and cumulative incidence of sac shrinkage ≥5 mm were significantly higher in the IMA embolization group than in the non-embolization group (95.5% vs 73.6% at 5 years; P = .021; 54.2% vs 33.6% at 5 years; P = .039, respectively). The freedom from T2EL-related sac enlargement ≥10 mm, an alternative indicator for T2EL-related reintervention, showed similar results (100% vs 90.4% at 5 years; P = .019). Outcomes in the low-risk group were preferable than those in the non-embolization group and comparable to those in the IMA embolization group. CONCLUSIONS: A lower threshold for pre-emptive IMA embolization when implementing EVAR would be more appropriate if limited to patients at high risk of T2ELs.
引用
- Takeuchi Y, Morikage N, Samura M, et al. Five-year follow-up of randomized clinical trial for pre-emptive inferior mesenteric artery embolization during endovascular aneurysm repair. J Vasc Surg. 2024. PMID: 38704104. doi:10.1016/j.jvs.2024.04.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。